➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
McKinsey
Colorcon
Baxter
Express Scripts

Last Updated: October 29, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,616,059

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,616,059
Title:Substituted indazole derivatives active as kinase inhibitors
Abstract: Substituted indazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a deregulated protein kinase activity, like cancer.
Inventor(s): Lombardi Borgia; Andrea (Paullo, IT), Menichincheri; Maria (Milan, IT), Orsini; Paolo (Legnano, IT), Panzeri; Achille (Merate, IT), Perrone; Ettore (Boffalora Sopra Ticino, IT), Vanotti; Ermes (Milan, IT), Nesi; Marcella (Saronno, IT), Marchionni; Chiara (Milan, IT)
Assignee: NERVIANO MEDICAL SCIENCES S.R.L. (Nerviano (MI), IT)
Application Number:14/971,372
Patent Claims: 1. A method for treating a patient having a cancer selected from the group consisting of ovarian cancer, lung cancer, colon cancer and lymphoma, comprising administering to said patient an effective amount of N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-- (tetrahydro-pyran-4-ylamino)-benzamide, or a pharmaceutically acceptable salt thereof, and an effective amount of at least one second therapeutic agent, wherein said at least one second therapeutic agent is selected from antihormonal agents, antiestrogens, antiandrogens, aromatase inhibitors, topoisomerase I inhibitors, topoisomerase II inhibitors, agents that target microtubules, platin-based agents, alkylating agents, DNA damaging agents, DNA intercalating agents, antineoplastic antimetabolites, kinase inhibitors, anti-angiogenic agents, inhibitors of kinesins, therapeutic monoclonal antibodies, mTOR inhibitors, histone deacetylase inhibitors, farnesyl transferase inhibitors, and hypoxic response inhibitors.

2. The method of claim 1, wherein said cancer is lung cancer.

3. The method of claim 1, wherein said cancer is colon cancer.

4. The method of claim 1, wherein said cancer is lymphoma.

5. The method of claim 1, wherein said cancer is ovarian cancer.

6. The method of claim 1, wherein said N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-- (tetrahydro-pyran-4-ylamino)-benzamide, or a pharmaceutically acceptable salt thereof, and said at least one second therapeutic agent are simultaneously administered to said patient.

7. The method of claim 1, wherein said N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-- (tetrahydro-pyran-4-ylamino)-benzamide, or a pharmaceutically acceptable salt thereof, and said at least one second therapeutic agent are sequentially administered to said patient.

8. The method according to claim 1, wherein said at least one second therapeutic agent is selected from kinase inhibitors.

9. The method according to claim 8, wherein said cancer is selected from lung cancer, colon cancer, ovarian cancer, and lymphoma.

10. The method of claim 9, wherein said cancer is lung cancer.

11. The method of claim 9, wherein said cancer is colon cancer.

12. The method of claim 9, wherein said cancer is ovarian cancer.

13. The method of claim 9, wherein said cancer is lymphoma.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Johnson and Johnson
Colorcon
AstraZeneca
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.